Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis

Key Inclusion Criteria: * Is diagnosed with active noninfectious intermediate-, posterior-, or pan-uveitis * Must have active uveitic disease at the Day 1/Baseline visit as defined by the presence of at least 1 of the following parameters in at least one eye despite 2 weeks of maintenance therapy with oral prednisone (≥ 10 mg/day to ≤ 60 mg/day) or an oral corticosteroid equivalent: * Active, inflammatory, chorioretinal and/or inflammatory retinal vascular lesion * ≥ 2+ anterior chamber cells per the Standardization of Uveitis Nomenclature (SUN) criteria * ≥ 2+ vitreous haze per the National Eye Institute/Standardization of Uveitis Nomenclature (NEI/SUN) criteria * No evidence of active tuberculosis (TB) or untreated latent TB Key Exclusion Criteria: * Participants with elevated intraocular pressures and/or severe glaucoma * Confirmed or suspected infectious uveitis, including but not limited to infectious uveitis due to TB, cytomegalovirus (CMV), Human T-Lymphotropic Virus Type 1 (HTLV-1), Whipple's disease, Herpes Zoster virus (HZV), Lyme disease, toxoplasmosis and herpes simplex virus (HSV) Note: Other protocol defined Inclusion/ Exclusion criteria may apply.